A new report from BIO shows just how chaotic the last few years have been for “emerging therapeutic companies” — basically, biotech companies that bring in less than $1 billion in sales.
The report, presented Tuesday at the trade organization’s annual convention, covered acquisitions, IPOs, and venture funding.
About the Author Reprints
